300,000 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by C WorldWide Group Holding A S

C WorldWide Group Holding A S bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 300,000 shares of the company’s stock, valued at approximately $15,177,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $26,000. Tennessee Valley Asset Management Partners bought a new stake in Ionis Pharmaceuticals during the 4th quarter worth about $34,000. Peoples Bank KS bought a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $39,000. China Universal Asset Management Co. Ltd. raised its holdings in Ionis Pharmaceuticals by 95.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,670 shares of the company’s stock worth $166,000 after purchasing an additional 1,795 shares during the last quarter. Finally, Mitchell & Pahl Private Wealth LLC bought a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $210,000. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Stock Down 0.6 %

Shares of Ionis Pharmaceuticals stock traded down $0.25 on Friday, reaching $41.59. 556,093 shares of the company were exchanged, compared to its average volume of 856,032. Ionis Pharmaceuticals, Inc. has a one year low of $34.32 and a one year high of $54.44. The company has a market capitalization of $6.06 billion, a price-to-earnings ratio of -16.25 and a beta of 0.39. The company has a current ratio of 5.90, a quick ratio of 5.83 and a debt-to-equity ratio of 3.18. The company has a 50-day moving average of $43.28 and a 200 day moving average of $47.16.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.72. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The business had revenue of $325.00 million for the quarter, compared to analysts’ expectations of $176.01 million. During the same quarter in the prior year, the business earned ($0.37) EPS. The firm’s revenue for the quarter was up 113.8% on a year-over-year basis. On average, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on IONS shares. Royal Bank of Canada boosted their price objective on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, January 26th. Bank of America upgraded Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $52.00 to $62.00 in a research report on Tuesday, January 2nd. Oppenheimer boosted their target price on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 9th. JPMorgan Chase & Co. boosted their target price on Ionis Pharmaceuticals from $52.00 to $55.00 and gave the stock a “neutral” rating in a research report on Thursday, February 1st. Finally, StockNews.com upgraded Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.08.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, CEO Brett P. Monia sold 23,501 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $49.37, for a total transaction of $1,160,244.37. Following the sale, the chief executive officer now directly owns 174,138 shares of the company’s stock, valued at approximately $8,597,193.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Eric Swayze sold 10,773 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $52.00, for a total value of $560,196.00. Following the sale, the executive vice president now directly owns 32,516 shares of the company’s stock, valued at $1,690,832. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brett P. Monia sold 23,501 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $49.37, for a total value of $1,160,244.37. Following the completion of the sale, the chief executive officer now directly owns 174,138 shares in the company, valued at $8,597,193.06. The disclosure for this sale can be found here. Insiders have sold a total of 42,699 shares of company stock valued at $2,104,091 in the last ninety days. 2.65% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.